BioStock: Scientific publication supports RhoVac’s cancer treatment method

RhoC is the target protein that Swedish biotech RhoVac uses in its ongoing immuno-oncology clinical trial in prostate cancer, BRaVac. New findings about RhoC’s function in the migration of cancer cells have been published in the scientific journal Cancer Cell International, thus giving RhoVac’s candidate broader support from the international scientific community.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/03/scientific-publication-supports-rhovacs-cancer-treatment-method/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se